Table 1 Baseline Demographic and Clinical Characteristics of Adult NEPTUNE Participants by Tobacco Exposure Groups
From: Tobacco exposure in adults and children with proteinuric glomerulopathies: a NEPTUNE cohort study
N (%) or Mean±SD N = 371 | Non-smoker N = 191 | Active smoker N = 54 | Former smoker N = 108 | Exclusive Passive smoker N = 18 | p-value |
|---|---|---|---|---|---|
Age | 43.7±16.3 | 47.6±13.5 | 49.5±16.0 | 41.5±15.0 | 0.01 |
Sex: Male | 106 (55.5%) | 37 (68.5%) | 76 (70.4%) | 6 (33.3%) | <0.01 |
Black Race | 39 (20.7%) | 22 (41.5%) | 18 (16.8%) | 5 (27.8%) | <0.01 |
Drug use | 9 (4.7%) | 12 (22.2%) | 18 (16.7%) | 1 (5.6%) | <0.01 |
Alcohol use: None | 97 (51.1%) | 25 (46.3%) | 40 (37.4%) | 9 (50.0%) | 0.27 |
Daily | 4 (2.1%) | 3 (5.6%) | 7 (6.5%) | 0 (0.0%) | Â |
3-4 times a week | 7 (3.7%) | 4 (7.4%) | 9 (8.4%) | 2 (11.1%) | Â |
1-2 times a week | 23 (12.1%) | 6 (11.1%) | 16 (15.0%) | 2 (11.1%) | Â |
1-2 times a month | 23 (12.1%) | 6 (11.1%) | 22 (20.6%) | 2 (11.1%) | Â |
< once a month | 36 (18.9%) | 10 (18.5%) | 13 (12.1%) | 3 (16.7%) | Â |
English as primary language | 142 (74.3%) | 46 (85.2%) | 83 (76.9%) | 12 (66.7%) | 0.30 |
Employment Status: Not Employed | 45 (23.7%) | 27 (50.0%) | 44 (40.7%) | 7 (38.9%) | <0.01 |
Employed | 127 (66.8%) | 26 (48.1%) | 62 (57.4%) | 10 (55.6%) | Â |
Homemaker | 10 (5.3%) | 0 (0.0%) | 0 (0.0%) | 1 (5.6%) | Â |
Not Applicable | 8 (4.2%) | 1 (1.9%) | 2 (1.9%) | 0 (0.0%) | Â |
Education Level: | Â | Â | Â | Â | 0.49 |
High School diploma | 45 (23.6%) | 9 (16.7%) | 21 (19.6%) | 2 (11.1%) | Â |
2-year Associates degree/certificate | 25 (13.1%) | 6 (11.1%) | 7 (6.5%) | 2 (11.1%) | Â |
4-year College degree | 25 (13.1%) | 6 (11.1%) | 12 (11.2%) | 1 (5.6%) | Â |
Master level diploma | 9 (4.7%) | 2 (3.7%) | 6 (5.6%) | 0 (0.0%) | Â |
Graduate level diploma | 4 (2.1%) | 1 (1.9%) | 2 (1.9%) | 1 (5.6%) | Â |
Not available | 8 (4.2%) | 5 (9.3%) | 2 (1.9%) | 2 (11.1%) | Â |
Unknown | 15 (7.9%) | 7 (13.0%) | 16 15.0%) | 4 (22.2%) | Â |
Weight (kg) | 88.4±28.4 | 91.7±27.8 | 85.6±21.3 | 84.1±22.7 | 0.49 |
Height (cm) | 169.1±10.6 | 171.5±10.2 | 171.0±10.3 | 165.2±12.0 | 0.08 |
BMI (kg/m2) | 30.4±8.1 | 30.8±9.1 | 29.3±7.2 | 30.6±6.7 | 0.63 |
Obesity | 83 (43.4%) | 26 (48.1%) | 38 (35.2%) | 9 (50%) | 0.28 |
Cohort: MN | 40 (21.1%) | 15 (28.3%) | 34 (31.8%) | 5 (27.8%) | 0.53 |
MCD | 37 (19.5%) | 11 (20.8%) | 15 (14.0%) | 2 (11.1%) | Â |
Other | 50 (26.3%) | 9 (17.0%) | 25 (23.4%) | 3 (16.7%) | Â |
FSGS | 63 (33.2%) | 18 (34.0%) | 33 (30.8%) | 8 (44.4%) | Â |
Hypertensive Status: Normal | 75 (1 (39.3%) | 14 (25.9%) | 39 (36.1%) | 11 (61.1%) | 0.62 |
Elevated BP | 84 (44.0%) | 26 (48.1%) | 37 (34.3%) | 6 (33.3%) | Â |
Hypertensive | 32 (16.8%) | 14 (25.9%) | 32 (29.6%) | 1 (5.6%) | Â |
SBP (mmHg) | 122.8±17.3 | 129.8±21.7 | 125.6±22.0 | 119.9±17.2 | 0.09 |
SBP Index | 0.79±0.13 | 0.78±0.15 | 0.75±0.15 | 0.79±0.12 | 0.25 |
DBP (mmHg) | 75.5±11.9 | 76.8±11.9 | 76.4±12.1 | 72.9±10.2 | 0.38 |
eGFR (ml/min/1.73m2) | 69.5±31.0 | 74.6±31.8 | 67.4±29.7 | 55.8±37.6 | 0.15 |
UPC ratio (g/g) | 3.3±4.5 | 4.0±5.4 | 3.7±3.8 | 4.2±3.9 | 0.71 |
Edema present | 85 (44.5%) | 29 (53.7%) | 49 (45.4%) | 10 (55.6%) | 0.56 |
Albumin (mg/dl) | 3.2± 0.10 | 2.9±0.9 | 3.1±1.0 | 3.0±1.0 | 0.56 |
Total Cholesterol (mg/dL) | 262.0±111.5 | 271.3±96.9 | 259.3±91.8 | 257.5±93.1 | 0.91 |
HDL (mg/dL) | 67.1±30.8 | 62.6±25.9 | 69.5±30.1 | 57.8±16.4 | 0.30 |
LDL (mg/dL) | 156.5±90.2 | 159.9±83.2 | 150.5±77.0 | 152.0±84.7 | 0.91 |
Triglycerides (mg/dL) | 192.2±128.4 | 243.9±152.0 | 196.8±162.3 | 238.4±156.2 | 0.08 |
Steroid use | 40 (20.9%) | 14 (25.9%) | 21 (19.4%) | 3 (16.7%) | 0.77 |
CNI use | 6 (3.1%) | 3 (5.6%) | 1 (0.9%) | 0 (0.0%) | 0.31 |
RAAS blocker use | 109 (57.1%) | 31 (57.4%) | 56 (51.9%) | 11 (61.1%) | 0.78 |
Arterial Hyalinosis | 0.35±0.55 | 0.43±0.86 | 1.02±1 | 0.19±0.53 | 0.11 |
Arteriosclerosis (%) | 0.81±0.9 | 0.93±0.56 | 0.23±0.46 | 0.31±0.46 | 0.17 |